Avalo Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Name: Avalo Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: Avalo Therapeutics Inc
Rating: 2.13575
Author: Trendlyne DVM scores

about

Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also incl...

11.60 1.44 (14.17%)

27.50% Fall from 52W High

362.3K

XNAS Volume

XNAS 05 Sep, 2025 5:30 PM (EDT)

Board Meeting

The next board meeting for Avalo Therapeutics Inc is on 15 Sep 2025 for the purpose of Stifel 2025 Virtual Immunology and Inflammation Forum See details

Not Eligible

Expensive Valuation

12.5 / 100

Technically Bullish

72.9 / 100

1Yr Price target upside is 166%

7 analysts

Avalo Therapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Avalo Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also incl...

27.50% Fall from 52W High

SWOT Analysis

Avalo Therapeutics Inc Live Price Chart